As Daiichi Sankyo-partnered breast cancer drug marches toward finish line, AstraZeneca brings in Canadian scientist Sunil Verma to rev up R&D
Months after AstraZeneca chief Pascal Soriot forced out MedImmune’s head of clinical oncology development Mohammed Dar in a sweeping restructuring, the British drugmaker is ushering in Sunil Verma as head of breast cancer strategy as part of its oncology R&D wing, as it sharpens its focus on its keenly anticipated Daiichi Sankyo-partnered antibody-drug conjugate.
Buoyed by the performance of AstraZeneca’s oncology drugs, in March Soriot bet big to partner with Daiichi Sankyo on its experimental breast cancer drug, with $1.35 billion upfront in a deal worth up to roughly $7 billion. Last week, the Japanese drugmaker said the therapy had cleared a pivotal mid-stage study, paving the way for regulatory submissions in the first half of fiscal 2019.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.